SSA
BOLT icon

Schonfeld Strategic Advisors’s Bolt Biotherapeutics BOLT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-960
Closed -$29K – 2609
2022
Q3 		$29K Sell
960
-195
-17% -$8.07K ﹤0.01% 2695
2022
Q2 		$48K Buy
1,155
+215
+23% +$8.35K ﹤0.01% 2227
2022
Q1 		$51K Buy
+940
New +$63.3K ﹤0.01% 2338

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Schonfeld Strategic Advisors's BOLT Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of Bolt Biotherapeutics (BOLT) in Q4 2022, closing a stake of 960 shares — an estimated $29K sold.

Schonfeld Strategic Advisors first reported a position in BOLT in Q1 2022 and held it in 3 quarters. The position peaked at $51K in Q1 2022. 44 funds tracked by Wall St. Rank hold BOLT as of Q4 2022.

  • Schonfeld Strategic Advisors reported no remaining Bolt Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 960 Bolt Biotherapeutics shares in Q4 2022, an estimated $29K.
  • Schonfeld Strategic Advisors first reported a position in Bolt Biotherapeutics in Q1 2022 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Bolt Biotherapeutics position peaked at $51K in Q1 2022.
  • 44 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.